Skip to main content
. 2022 Jun 29;77(3):308–315. doi: 10.1038/s41430-022-01176-5

Fig. 2. Meta-regression analysis of trials with 120 min follow-up durations assessing the effect of OBG dose on glucose iPeak in subjects without diabetes.

Fig. 2

Footnotes MW, molecular weight; OBG, Oat β-glucan; iPeak, peak increment; avCHO, available carbohydrate; RoM, ratio of means; CIs, confidence intervals. A–C: Pooled dose-response relationships for: (A) low MW (<300 kg/mol); (B) medium MW (300–1000 kg/mol); and C, high MW (>1000 kg/mol) OBG on glucose iPeak. Individual comparisons are represented by the circles, with the weight of the study in the overall analysis represented by the size of the circles: open circles, healthy subjects. Solid lines are the estimated linear dose responses; gray dashed lines, upper and lower 95% CI is; vertical black dashed lines, minimum OBG dose required to reduce glucose iPeak with 95% certainty (there is no such line on panel C because the upper 95% CI is <y = 1 at the lowest dose studied, 0.2 g/30 g avCHO). D–F: effect of OBG on glucose iAUC (expressed as RoM with 95% CI) for individual studies with: (D) low; (E) medium; and (F) high MW OBG. Trial comparisons are sorted from the lowest (top) to the highest (bottom) dose of OBG per 30 g avCHO.